Best deal of the week



Instruction for use: Diprivan

I want this, give me price

Dosage form: emulsion for intravenous administration

Active substance: Propofol*


N01AX10 Propofol

Pharmacological group:

Anesthetic means

The nosological classification (ICD-10)

Z100.0 * Anesthesiology and premedication: Abdominal surgery; Adenomectomy; Amputation; Angioplasty of the coronary arteries; Carotid artery angioplasty; Antiseptic treatment of skin in wounds; Antiseptic treatment of hands; Appendectomy; Atheroctomy; Balloon coronary angioplasty; Vaginal hysterectomy; Venous bypass; Interventions on the vagina and cervix; Interventions on the bladder; Interference in the oral cavity; Reconstructive-reconstructive operations; Hand hygiene of medical personnel; Gynecological Surgery; Gynecological interventions; Gynecological operations; Hypovolemic shock during surgery; Disinfection of purulent wounds; Disinfection of the edges of wounds; Diagnostic Interventions; Diagnostic procedures; Diathermocoagulation of the cervix; Long-term surgeries; Replacement of fistulous catheters; Infection in orthopedic surgical interventions; Artificial heart valve; Kistectomy; Short-term outpatient surgery; Short-term operations; Short-term surgical procedures; Cryotyreotomy; Blood loss during surgical interventions; Bleeding during surgery and in the postoperative period; Kuldotsentez; Laser coagulation; Laserocoagulation; Laser retinopathy of the retina; Laparoscopy; Laparoscopy in gynecology; Likvornaya fistula; Small gynecological operations; Small surgical interventions; Mastectomy and subsequent plastic surgery; Mediastinotomy; Microsurgical operations on the ear; Mukinging operations; Suturing; Minor surgery; Neurosurgical operation; Eclipse of the eyeball in ophthalmic surgery Orchiectomy; Pancreatectomy; Pericardectomy; The rehabilitation period after surgical operations; Reconvalence after surgical intervention; Percutaneous transluminal coronary angioplasty; Pleural Thoracocentesis; Pneumonia postoperative and post traumatic; Preparing for surgical procedures; Preparing for a surgical operation; Preparation of the surgeon's arms before surgery; Preparation of the colon for surgical interventions; Postoperative aspiration pneumonia in neurosurgical and thoracic operations; Postoperative nausea; Postoperative hemorrhage; Postoperative granuloma; Postoperative shock; Early postoperative period; Myocardial revascularization; Resection of the apex of the tooth root; Resection of the stomach; Bowel resection; Resection of the uterus; Liver resection; Small bowel resection; Resection of a part of the stomach; Reocclusion of the operated vessel; Gluing of tissues during surgical interventions; Suture removal; Condition after eye surgery; Condition after surgery; Condition after surgery in the nasal cavity;Condition after gastrectomy; Condition after resection of the small intestine; Condition after tonsillectomy; Condition after removal of duodenum; Condition after phlebectomy; Vascular Surgery; Splenectomy; Sterilization of surgical instrument; Sterilization of surgical instruments; Sternotomy; Dental surgery; Dental intervention on periodontal tissues; Strumectomy; Tonsillectomy; Thoracic surgery; Total gastrectomy; Transdermal intravascular coronary angioplasty; Transurethral resection; Turbinectomy; Removal of a tooth; Cataract removal; Removing Cysts; Removal of tonsils; Removal of myoma; Removal of mobile milk teeth; Removal of polyps; Removal of a broken tooth; Removal of the uterus; Removal of seams; Urethrotomy; Fistula of the luminal ducts; Frontoetmoidohaimorotomy; Surgical infection; Surgical treatment of chronic ulcers of extremities; Surgery; Surgery in the anus; Surgery on the large intestine; Surgical practice; Surgical procedure; Surgical interventions; Surgical interventions on the digestive tract; Surgical interventions on the urinary tract;Surgical interventions on the urinary system; Surgical interventions on the genitourinary system; Surgical intervention on the heart; Surgical procedures; Surgical operations; Surgical operations on veins; Surgical intervention; Vascular; Cholecystectomy; Partial resection of the stomach; Extraperitoneal hysterectomy; Percutaneous transluminal coronary angioplasty; Percutaneous transluminal angioplasty; Coronary artery bypass grafting; Extirpation of the tooth; Extirpation of infant teeth; Extirpation of pulp; Extracorporeal circulation; Extraction of the tooth; Extraction of teeth; Extraction of cataracts; Electrocoagulation; Endourological interventions; Episiotomy; Ethmoidotomy; Complications after tooth extraction

Composition and release form

Emulsion for intravenous administration 1 ml

propofol 10 mg

auxiliary substances: soybean oil - 100 mg; phospholipids of egg yolk - 12 mg; glycerol 22.5 mg; disodium EDTA (anhydrous equivalent) - 0.055 mg; sodium hydroxide in an amount necessary to adjust the pH to 7.5-8.5; water for injection - up to 1 ml

in glass ampoules of 20 ml, 5 ampoules in a plastic holder, in a pack of cardboard or 50 ml in a glass syringe with a polypropylene plunger and a Luer connector; in a contourcell pack, 1 syringe; in a pack of cardboard 1 package.

Description of dosage form

White or almost white color is a homogeneous emulsion. With prolonged standing, a slight stratification can be observed.

Pharmachologic effect

Pharmacological action is general anesthetic.

Indications for the Diprivan

induction and maintenance of general anesthesia;

sedation of patients on mechanical ventilation during intensive therapy;

sedation of patients who are conscious during surgical and diagnostic procedures.


hypersensitivity to any of the components of the drug;

induction and maintenance of general anesthesia in children younger than 1 month;

sedation of patients under the age of 16 years who are on mechanical ventilation during intensive therapy;

sedation of patients under the age of 16 who are conscious, during the surgical and diagnostic procedures;

pregnancy, and also use in obstetrical practice, except for the termination of pregnancy in the first trimester;

the period of breastfeeding.

With caution: as with the use of other intravenous anesthetics, caution should be exercised in patients with cardiovascular, respiratory, renal or hepatic impairment, as well as in patients with epilepsy, hypovolemia, lipid metabolism disorders or in weakened patients.

Application in pregnancy and lactation


Diprivan® should not be used during pregnancy. However, Diprivan® is used during the termination of pregnancy in the first trimester.


Diprivan® penetrates the placental barrier and its use can be associated with neonatal depression. It should not be used in obstetrics as an anesthetic.

Breastfeeding period

For infants who are breastfed, the safety of Diprivan® in lactating women has not been established. In this regard, breastfeeding is not recommended during the use of Diprivan®.

Side effects

As a rule, induction of anesthesia proceeds with minimal signs of excitation. The most common adverse reactions are pharmacology-predictable side effects of any agent for general anesthesia, for example, lowering blood pressure. Cases reported in connection with anesthesia and intensive care may also be related to ongoing procedures or to the condition of the patient.

Very often (> 1/10) General reactions and reactions at the site of administration: pain at the injection site with induction of anesthesia1
Often (> 1/100, <1/10) Are common: withdrawal syndrome in children4
From the CAS side: a decrease or increase in AD2, bradycardia, 3 a rush of blood in children4
From the digestive tract: Vomiting and nausea during awakening
From the side of the central nervous system: headache during awakening
From the respiratory system: temporary apnea during induction of anesthesia
Infrequently (> 1/1000, <1/100) From the CAS side: arrhythmia, thrombosis and phlebitis
Rarely (> 1/10000, <1/1000) Disorders from the central nervous system: epileptiform seizures, including convulsions and opisthotonus during induction of anesthesia, maintenance of anesthesia and awakening
Very rarely (<1/10000) Very often (> 1/10) Often (> 1/100, <1/10)

Infrequently (> 1/1000, <1/100)

Musculoskeletal effects, connective tissue: rhabdomyolysis5
Procedural complications: postoperative fever
From the digestive tract: pancreatitis
From the side of the kidneys and urinary system: bleaching of urine with long-term administration
From the immune system: Anaphylaxis can manifest itself in the form of: angioedema, bronchospasm, erythema, and lowering blood pressure
Disorders from the reproductive system: sexual disinhibition
From the CAS side: asystole, pulmonary edema
From the side of the central nervous system: postoperative unconsciousness
1 Pain at the injection site can be reduced by injecting the drug into larger forearm veins and an elbow fold. Pain sensations can also be reduced by the joint administration of the drug Diprivan® with lidocaine (see section "Dosing and Administration", part D)2 Reduction of blood pressure can cause the need for / in the introduction of fluid and reduce the rate of administration of the drug Diprivan.

3 Serious cases of bradycardia are rare. There are isolated reports of progression of the bradycardia up to asystole.

4 Occurs during the abrupt discontinuation of Diprivan® during intensive care.

5 Very few cases of rhabdomyolysis were reported with Diprivant® at doses greater than 4 mg / kg / h for sedation in intensive care.

During the induction of anesthesia, slight excitation may be observed depending on the dose of Diprivan® and concomitant therapy.

In very rare cases, when taking Diprivan® at doses of more than 4 mg / kg / h for sedation in intensive care, cases of metabolic acidosis, hyperkalemia and heart failure, sometimes fatal, have been reported.

There have been reports of cases of dystonia, dyskinesia and hyperlipidemia.

In the phase of awakening, sometimes chills, a feeling of cold, dizziness, coughing can be observed.

Dosing and Administration

As a rule, Diprivan® requires additional use of analgesics.

Diprivan® is combined with spinal and epidural anesthesia; with drugs commonly used for premedication; with muscle relaxants, means for inhalation anesthesia and analgesics, while there was no pharmacological incompatibility. Lower doses of Diprivan® may be required in cases where general anesthesia is used as a supplement to the methods of regional anesthesia used.

Guidelines for the administration of Diprivan® to the target concentration using an infusion system that includes the appropriate "Diprifuser" software, see section D. This use is limited to induction and maintenance of general anesthesia in adults. The infusion system for the target concentration (DTS) "Diprifuge" is not recommended for sedation in patients in intensive care units, for a sedative effect with consciousness, or in children.


Induction of general anesthesia

Diprivan® can be used to induce anesthesia through slow bolus injections or infusion. Regardless of whether premedication was or was not conducted, the administration of Diprivan® is recommended to be titrated (bolus injections or infusion of approximately 40 mg every 10 seconds - for the average adult in a satisfactory state), depending on the patient's response to the appearance of clinical signs of anesthesia. For most adult patients under 55 years of age, the average dose of Diprivan® is 1.5-2.5 mg / kg. The required total dose can be reduced using lower administration rates (20-50 mg / min). For patients older than this age, usually a lower dose is required. Patients 3 and 4 of the ASA Classification (ASA) classification should be administered at a lower rate (approximately 20 mg every 10 seconds).

Maintaining general anesthesia

Anesthesia can be maintained either by a constant infusion of the Diprivan® drug, or by repeated bolus injections necessary to maintain the required depth of anesthesia.

Constant infusion. The required rate of administration varies greatly depending on the individual characteristics of the patients. Typically, a rate of between 4-12 mg / kg / h ensures adequate anesthesia.

Repeated bolus injections. If a technique involving repeated bolus injections is used, then the administration of increasing doses of 25 to 50 mg, depending on the clinical need, is used.

Sedation during intensive care

The introduction of Diprivan® with the help of the Diprifuge system for sedation of patients during intensive therapy is not recommended.

When using the drug Diprivan ® for sedation of adult patients who are on ventilation and receiving intensive therapy, it is recommended to use it through continuous infusion. The rate of infusion should be adjusted to the required depth of sedation, but a rate of 0.3-4 mg / kg / h should ensure satisfactory sedation. The infusion rate should not exceed 4 mg / kg / h, unless the potential benefit to the patient outweighs the risk of side effects.

Sedation of patients who are conscious, during surgical and diagnostic procedures

The introduction of Diprivan® with the help of the Diprifuge system for sedation with preservation of consciousness is not recommended.

To ensure sedation during surgical and diagnostic procedures, the rate of administration and dosage should be selected individually depending on the clinical response of the patient.

For most patients, 0.5-1 mg / kg is required for 1-5 minutes for the onset of sedation.

To maintain sedation, the infusion rate should be adjusted according to the required depth of sedation; for most patients, a rate of 1.5-4.5 mg / kg / h is required. If a rapid increase in the depth of sedation is required, bolus administration of 10-20 mg of Diprivan® can be used as an adjunct to the infusion. For patients in grade 3 and 4, ASA may require a reduction in dose and rate of administration.

B. Older patients

Older patients require lower doses of Diprivan® for anesthesia. When reducing the dose should be guided by the physical status and age of the patient. A reduced dose should be administered at a lower rate than usual and titrated according to the patient's response. When using Diprivan® to maintain anesthesia or sedation, the infusion rate or "target concentration" of the drug should be reduced. For patients in grade 3 and 4, ASA may require a further reduction in dose and rate of administration. To avoid oppression of the cardiovascular and respiratory systems, elderly patients are not recommended for rapid bolus administration (single or repeated).


Children are not recommended to administer Diprivan® with the help of the Diprifusor system for any indication.

Induction of general anesthesia

Diprivan® is not recommended for use in children under 1 month of age (see "Contraindications").

When using the drug Diprivan ® in order to ensure the induction of anesthesia in children, it is recommended to inject it slowly until the appearance of clinical signs of anesthesia. The dose should be adjusted according to the age and / or body weight of the child. For most children over the age of 8, approximately 2.5 mg / kg of Diprivan® is probably needed to induce anesthesia. For children aged 1 month to 8 years, the required dose may be higher. A lower dose is recommended for children of grade 3 and 4 ASA.

Maintaining general anesthesia

Diprivan® is not recommended for use in children under 1 month of age.

Maintenance of anesthesia is achieved by administering Diprivan® through continuous infusion or by repeated bolus injections required to maintain the required depth of anesthesia. The required rate of administration differs significantly in different patients; satisfactory anesthesia is usually provided at infusion rate of 9-15 mg / kg / h.

Sedation of patients who are conscious, during surgical and diagnostic procedures

Diprivan® is not recommended for sedation with conscious consciousness in children, since its safety and effectiveness in this application have not yet been confirmed.

Sedation during intensive care

Diprivan® is not recommended for sedation in children; its safety and effectiveness in this application have not yet been confirmed. With unlicensed use, serious adverse events (including deaths) were noted, although there was no causal relationship with Diprivan®. These adverse events were most often observed in children with respiratory tract infections that received doses exceeding the recommended doses for adults.


Diprivan® can be administered undiluted using plastic syringes or glass vials for infusion or filled with Diprivan® glass syringes. In cases where Diprivan® is used in undiluted form to maintain general anesthesia, it is recommended to always use perfusors or infusomats in order to control the rate of administration.

Diprivan® can also be used diluted with only 5% dextrose solution, intended for intravenous administration, in PVC bags or in glass bottles. The solution, the dilution of which should not exceed a ratio of 1: 5 (2 mg / ml propofol), should be prepared in accordance with the rules of aseptic immediately before use. The mixture is stable for 6 hours.

A diluted solution of Diprivan® can be administered using a variety of adjustable infusion systems, but the use of only such devices does not completely avoid the risk of accidental, uncontrolled administration of large volumes of diluted Diprivan®. Burettes, drip counters or dosing pumps should always be part of the infusion line. When choosing the maximum volume of diluted Diprivan ® in burette, one should bear in mind the risk of uncontrolled administration.

Diprivan® can be administered via a tee with a valve close to the injection site, concomitantly with the administration of a 5% dextrose solution for intravenous administration, 0.9% sodium chloride solution for IV administration or 4% dextrose solution with 0.18% sodium solution chloride for intravenous administration.

A ready-to-use glass syringe has less piston resistance than a plastic disposable syringe and is easier to drive. When Diprivan® is administered manually with a ready-to-use glass syringe, the infusion system between the syringe and the patient should not be left open if there is no observation from the medical staff.

Appropriate compatibility should be ensured if a ready-to-use glass syringe is used in a syringe pump. In particular, the design of the pump must prevent siphoning and should provide an alarm for clogging at a pressure of not more than 1000 mm Hg. If a programmable pump or an equivalent pump is used, assuming the possibility of using different syringes, then in the case of a ready-to-use glass syringe, only the "B-D" mode of 50/60 ml of PLASTIPAK is selected.

Diprivan® can be pre-mixed with alfentanil for injection containing 500 μg / ml of alfentanil, in a volume ratio of 20: 1-50: 1. Mixtures should be prepared using sterile equipment, and applied within 6 hours after preparation.

To reduce pain at the start of the injection, the induction dose of the Diprivan preparation immediately before administration can be mixed with lidocaine for injection in a plastic syringe in the following proportion: 20 parts of Diprivan® and up to one part of either 0.5 or 1% lidocaine for injection.

Diprivan® dilution and co-administration in combination with other drugs or infusion solutions

Method of simultaneous application Drug or infusion solution Preparation Caveats
Pre-mixing 5% dextrose solution for intravenous administration Mix 1 part of Diprivan® and up to 4 parts of 5% dextrose solution for iv administration or in PVC bags or in glass bottles. When diluted in PVC bags it is recommended that the bag be full, the solution is prepared by removing a portion of the volume of the dextrose solution, replacing it with an equivalent volume of the Diprivan® preparation Cook in aseptic conditions, immediately before use. The mixture is stable for 6 hours.
Lidocaine for injection (0.5 or 1% without preservatives) Mix 20 parts of the Diprivan® preparation and up to 1 part of a 0.5 or 1% solution of lidocaine for injection Cook, observing the conditions of aseptic, immediately before use. To be used only for the induction of anesthesia
Alfentanil for injection (500 μg / ml) Mix Diprivan® with alfentanil for injection in a volume ratio of 20: 1-50: 1 Cook, observing the conditions of aseptic, immediately before use. Apply within 6 hours after preparation
Simultaneous introduction of a tee with a valve Method of simultaneous application Pre-mixing 5% dextrose solution for intravenous administration Simultaneous administration using a tee with a valve The tee with the valve should be placed close to the injection site
0.9% solution of sodium chloride for iv introduction See above See above
4% dextrose solution with 0.18% sodium chloride solution for iv administration See above See above


The introduction of Diprivan® with the Diprifuge system is limited to periods of induction and maintenance of general anesthesia in adults. It is not recommended to use sedation in intensive care, to provide a sedative effect with the preservation of consciousness or in children.

Diprivan® can be introduced by the ICC method only with the help of the Diprifusor ICP system, which includes the Diprifuser software. These systems will function only after recognizing the electronic label on a ready-to-use glass syringe filled with Diprivan®.

The Diprifuge system will automatically adjust the rate of administration of Diprivan® to the concentration that was recognized by the system. Users should be familiarized with the manual for working with the infusion pump, with the introduction of Diprivan® by the ICC method, with the correct use of the syringe recognition system, as described in the training manual provided by AstraZeneca.

This system enables the anesthesiologist to achieve and control the induction rate and depth of anesthesia by setting and adjusting the target (predicted) concentration of propofol in the patient's blood.

The Diprifyuzor system assumes that the initial concentration of propofol in the patient's blood is 0. Therefore, for patients who received propofol previously, it is possible to select lower initial target concentrations at the onset of Diprivan® administration with the help of the Diprifuge. Also, it is not recommended to resume the work of the Diprifyuzor IC in the previous mode after it was shut down.

Guidance on the selection of target concentrations of propofol is attached below. Due to the individual differences in the pharmacokinetics and pharmacodynamics of propofol in patients who received premedication and who did not receive it, the target concentration of propofol should be titrated depending on the patient's clinical response in order to achieve the required depth of anesthesia.

In adult patients under 55 years of age, anesthesia can usually be induced by targeted concentrations of propofol from 4 to 8 μg / ml. The initial target concentration of propofol 4 μg / ml is recommended for patients who have been premedicated, a concentration of 6 μg / ml is recommended for patients without premedication. The time of induction of anesthesia at these target concentrations is, as a rule, 60-120 s. Higher values will lead to faster induction of anesthesia, but may be associated with more severe hemodynamic depression and respiratory function.

Smaller initial target concentrations should be used in patients older than 55 years and in patients in grade 3 and 4 ASA. Target concentrations can then be gradually increased by a value from 0.5 to 1.0 μg / ml at intervals of 1 min to achieve gradual induction of anesthesia.

As a rule, additional analgesia is required, and the amount of reduction in target concentrations to maintain anesthesia will depend on the amount of additional analgesics administered. Target concentrations of propofol in the range of 3 to 6 μg / ml usually maintain a sufficient level of general anesthesia.

The predicted concentration of propofol upon awakening is generally within 1-2 μg / ml and will depend on the level of analgesia during the period of maintenance of anesthesia.

Sedation during intensive care

Usually, a target concentration of propofol in the blood in the range of 0.2-2.0 μg / ml is required. The administration of Diprivan® should be started at a low target concentration and titrated with dose depending on the patient's response to achieve the desired sedation depth.


Accidental overdose, probably, can cause oppression of CCC and respiration. In case of respiratory depression, ventilation with oxygen should be performed. When oppression of cardiovascular activity in severe cases, it may be necessary to introduce plasma-substituting and pressor means.

Special instructions

Diprivan® should not be mixed with any other injectable or infusion solutions before use with the exception of 5% dextrose in PVC bags or in glass infusion bottles, lidocaine for injection or alfentanil for injection in plastic syringes.

With the introduction of muscle relaxants atrakury bezilata and myakuriya chloride, do not use the same infusion line as for Diprivan®, without first rinsing it.

Diprivan® should be used by personnel trained in anesthesia (or, if appropriate, by physicians trained to assist patients during intensive care). Patients should be constantly monitored, equipment to maintain free airway patency, for artificial ventilation, oxygen enrichment, as well as other resuscitation facilities should be constantly ready for use. Diprivan® should not be administered by a person performing a diagnostic or surgical procedure.

When using Diprivan® during surgical or diagnostic procedures for conscious sedation, constant monitoring of the patient is necessary to identify early signs of a reduction in blood pressure, airway obstruction, and insufficient oxygen saturation with blood.

As with the use of other sedatives, with the introduction of the drug Diprivan ® to provide sedative effect during surgery, involuntary movements of patients are possible. In procedures requiring immobility, these movements may be dangerous for the site of surgery.

An adequate period of time is needed to monitor the patient to ensure complete recovery after general anesthesia. In very rare cases, after using the Diprivan® drug, there may be a lack of consciousness in the postoperative period, which may be accompanied by an increase in muscle tone. Sometimes a loss of consciousness occurs after a period of wakefulness. In spite of a spontaneous awakening, the patient, who is in an unconscious state, must be properly supervised.

Diprivan® has a weak m-cholinoblocking activity and its use is associated with cases of bradycardia (which is sometimes serious), as well as with asystole. It is advisable to inject m-holinoblokiruyuschego funds before or during the induction of anesthesia, especially in those cases when there is a possibility of a predominance of the tone of the vagus nerve, or when Diprivan® is used in combination with other agents that can cause bradycardia.

In the event that Diprivan® is administered to a patient suffering from epilepsy, there is a risk of seizures.

Appropriate attention should be given to patients with lipid metabolism disorders, as well as other conditions requiring careful application of lipid emulsions.

It is recommended to monitor the concentration of lipids in the blood in cases where Diprivan® is prescribed to patients who are at particular risk of lipid accumulation. In the event that monitoring indicates an inadequate removal of fats from the body, the administration of Diprivan® should be corrected as appropriate. With simultaneous IV administration of a patient to another lipid drug, the dose should be reduced, taking into account the amount of lipid introduced into the Diprivan® preparation; 1.0 ml of Diprivan® contains approximately 0.1 g of lipids.

A note on the section "Sedation during intensive care"

Very rare cases of metabolic acidosis, rhabdomyolysis, hyperkalemia, and / or congestive heart failure have been reported, in some cases fatal in severely ill patients receiving Diprivan® to provide a sedative effect during intensive care. The most likely risk factors for these events were: decreased oxygen supply to the tissues, serious neurological injuries and / or sepsis, high doses of the following pharmacologically active agents - vasoconstrictors, steroids, cardiotonic agents and / or propofol. All sedative and therapeutic drugs used during intensive care (including Diprivan®) should be titrated to maintain optimum oxygen supply to the tissues and optimal hemodynamic parameters.

The EDTA that forms part of the preparation forms chelate complexes with metal ions, including zinc ions. Consideration should be given to the possibility of additional zinc supplementation with prolonged use of Diprivan, especially in patients who are predisposed to zinc deficiency, for example, burns, diarrhea, and / or sepsis.

Diprivan® does not contain antimicrobial preservatives and can serve as a favorable medium for the growth of microorganisms. When Diprivan® is filled with a sterile syringe or infusion line, aseptic rules should be followed; the drug should be recruited immediately after opening the ampoule. The introduction should begin immediately. Aseptic conditions must be ensured throughout the infusion period both with regard to the Diprivan® preparation and the equipment for administration. Any infusion solutions added to the infusion line in conjunction with the Diprivan® preparation should be administered as close as possible to the location of the cannula. Diprivan® can not be administered via a microbiological filter.

Syringe with Diprivan® is a disposable and is intended for use in one patient. According to the rules established for other lipid emulsions, the duration of continuous infusion of Diprivan® should not exceed 12 hours. At the end of the infusion of the drug or after a 12-hour period, it is necessary to replace both the container with the Diprivan® preparation and the infusion line.

Containers with Diprivant® should be shaken before use. The contents of the container, left in any quantity after its use, must be destroyed.

Aseptic conditions should be provided for both the Diprivan® preparation and the administration equipment.

Influence on the ability to drive and other mechanisms. Patients should be informed that general anesthesia, for some time after it, may worsen the performance of skills requiring work, such as driving or working with machinery.

A comment

Before using the drug, read the instructions for use.

Conditions of leave from pharmacies

On prescription.

Storage conditions for Diprivan

At a temperature of 2-25 ° C (do not freeze)

Keep out of the reach of children.

Shelf life of Diprivan

emulsion for intravenous administration of 10 mg / ml - 3 years.

emulsion for intravenous administration of 10 mg / ml - 3 years.

Do not use after the expiry date printed on the package.

Someone from the Australia - just purchased the goods:
Cerluten intensive course 180 capsules